{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T02:15:52Z","timestamp":1788833752302,"version":"build-2803163510"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T00:00:00Z","timestamp":1757289600000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100010733","name":"B\u00f8rnecancerfonden","doi-asserted-by":"publisher","award":["2021-7410"],"award-info":[{"award-number":["2021-7410"]}],"id":[{"id":"10.13039\/100010733","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010733","name":"B\u00f8rnecancerfonden","doi-asserted-by":"publisher","award":["2022-8178"],"award-info":[{"award-number":["2022-8178"]}],"id":[{"id":"10.13039\/100010733","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007460","name":"Arvid Nilssons Fond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007460","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Director Michael Hermann Nielsen\u2019s Memorial Foundation","award":["2022-0097724"],"award-info":[{"award-number":["2022-0097724"]}]},{"name":"Engineer Otto Christensen's Foundation"},{"name":"Manufacturer Einar Willumsen\u2019s Memorial Foundation"},{"DOI":"10.13039\/501100006442","name":"Det Sundhedsvidenskabelige Fakultet, K\u00f8benhavns Universitet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006442","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001734","name":"Copenhagen University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001734","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s11523-025-01172-2","type":"journal-article","created":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T11:23:29Z","timestamp":1757330609000},"page":"871-886","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Published Population Pharmacokinetic Models of Imatinib Perform Poorly on TDM Data from Pediatric Patients"],"prefix":"10.1007","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-0856-4497","authenticated-orcid":false,"given":"Tianwu","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4997-2914","authenticated-orcid":false,"given":"Anna Sofie Buhl","family":"Rasmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan","family":"Weimann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9950-5911","authenticated-orcid":false,"given":"Maria","family":"Thastrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0578-3887","authenticated-orcid":false,"given":"Cecilie Utke","family":"Rank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bodil","family":"Als-Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7274-2957","authenticated-orcid":false,"given":"Johan","family":"Malmros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1035-5521","authenticated-orcid":false,"given":"Hilde Skuterud","family":"Wik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9195-0797","authenticated-orcid":false,"given":"Olli","family":"Lohi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrik","family":"Overgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inga Maria Rinvoll","family":"Johannsdottir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6724-8164","authenticated-orcid":false,"given":"Goda","family":"Vaitkeviciene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5548-6381","authenticated-orcid":false,"given":"Kim","family":"Dalhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0829-4993","authenticated-orcid":false,"given":"Kjeld","family":"Schmiegelow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8598-2880","authenticated-orcid":false,"given":"Trine Meldgaard","family":"Lund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,8]]},"reference":[{"key":"1172_CR1","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1056\/NEJMe1700833","volume":"376","author":"DL Longo","year":"2017","unstructured":"Longo DL. Imatinib changed everything. N Engl J Med. 2017;376:982\u20133.","journal-title":"N Engl J Med"},{"key":"1172_CR2","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1080\/17512433.2024.2312256","volume":"17","author":"AS Buhl Rasmussen","year":"2024","unstructured":"Buhl Rasmussen AS, Andersen CL, Weimann A, Yang T, Tron C, Gandemer V, et al. Therapeutic drug monitoring of imatinib: how far are we in the leukemia setting? Expert Rev Clin Pharmacol. 2024;17:225\u201334.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"1172_CR3","doi-asserted-by":"crossref","first-page":"879","DOI":"10.2165\/00003088-200544090-00001","volume":"44","author":"B Peng","year":"2005","unstructured":"Peng B, Lloyd P, Schran H. Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44:879\u201394.","journal-title":"Clin Pharmacokinet"},{"key":"1172_CR4","doi-asserted-by":"crossref","first-page":"731","DOI":"10.3324\/haematol.2011.045666","volume":"97","author":"F Guilhot","year":"2012","unstructured":"Guilhot F, Hughes TP, Cortes J, Druker BJ, Baccarani M, Gathmann I, et al. Plasma exposure of imatinib and its correlation with clinical response in the tyrosine kinase inhibitor optimization and selectivity trial. Haematologica. 2012;97:731\u20138.","journal-title":"Haematologica"},{"key":"1172_CR5","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/fcp.12007","volume":"27","author":"S Bouchet","year":"2013","unstructured":"Bouchet S, Titier K, Moore N, Lassalle R, Ambrosino B, Poulette S, et al. Therapeutic drug monitoring of imatinib in chronic myeloid leukemia: experience from 1216 patients at a centralized laboratory. Fundam Clin Pharmacol. 2013;27:690\u20137.","journal-title":"Fundam Clin Pharmacol"},{"key":"1172_CR6","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2217\/pgs-2016-0103","volume":"18","author":"Z-P Jiang","year":"2017","unstructured":"Jiang Z-P, Zhao X-L, Takahashi N, Angelini S, Dubashi B, Sun L, et al. Trough concentration and ABCG2 polymorphism are better to predict imatinib response in chronic myeloid leukemia: a meta-analysis. Pharmacogenomics. 2017;18:35\u201356.","journal-title":"Pharmacogenomics"},{"key":"1172_CR7","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1016\/j.ejca.2014.04.015","volume":"50","author":"N Widmer","year":"2014","unstructured":"Widmer N, Bardin C, Chatelut E, Paci A, Beijnen J, Lev\u00eaque D, et al. Review of therapeutic drug monitoring of anticancer drugs part two: targeted therapies. Eur J Cancer. 2014;50:2020\u201336.","journal-title":"Eur J Cancer"},{"key":"1172_CR8","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1038\/sj.bjc.6605584","volume":"102","author":"N Widmer","year":"2010","unstructured":"Widmer N, Decosterd LA, Csajka C, Montemurro M, Haouala A, Leyvraz S, et al. Imatinib plasma levels: correlation with clinical benefit in GIST patients. Br J Cancer. 2010;102:1198\u20139.","journal-title":"Br J Cancer"},{"key":"1172_CR9","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1200\/JCO.2008.20.4818","volume":"27","author":"GD Demetri","year":"2009","unstructured":"Demetri GD, Wang Y, Wehrle E, Racine A, Nikolova Z, Blanke CD, et al. Imatinib plasma levels are correlated with clinical benefit in patients with unresectable\/metastatic gastrointestinal stromal tumors. J Clin Oncol. 2009;27:3141\u20137.","journal-title":"J Clin Oncol"},{"key":"1172_CR10","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","volume":"109","author":"S Picard","year":"2007","unstructured":"Picard S, Titier K, Etienne G, Teilhet E, Ducint D, Bernard M-A, et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood. 2007;109:3496\u20139.","journal-title":"Blood"},{"key":"1172_CR11","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","volume":"111","author":"RA Larson","year":"2008","unstructured":"Larson RA, Druker BJ, Guilhot F, O\u2019Brien SG, Riviere GJ, Krahnke T, et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood. 2008;111:4022\u20138.","journal-title":"Blood"},{"key":"1172_CR12","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1248\/bpb.b15-00103","volume":"38","author":"M Miura","year":"2015","unstructured":"Miura M. Therapeutic drug monitoring of imatinib, nilotinib, and dasatinib for patients with chronic myeloid leukemia. Biol Pharm Bull. 2015;38:645\u201354.","journal-title":"Biol Pharm Bull"},{"key":"1172_CR13","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1016\/j.clinthera.2019.10.009","volume":"41","author":"M Garc\u00eda-Ferrer","year":"2019","unstructured":"Garc\u00eda-Ferrer M, Wojnicz A, Mej\u00eda G, Koller D, Zubiaur P, Abad-Santos F. Utility of therapeutic drug monitoring of imatinib, nilotinib, and dasatinib in chronic myeloid leukemia: a systematic review and meta-analysis. Clin Ther. 2019;41:2558-70.e7.","journal-title":"Clin Ther"},{"key":"1172_CR14","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1038\/sj.bjc.6604355","volume":"98","author":"N Widmer","year":"2008","unstructured":"Widmer N, Decosterd LA, Leyvraz S, Duchosal MA, Rosselet A, Debiec-Rychter M, et al. Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability. Br J Cancer. 2008;98:1633\u201340.","journal-title":"Br J Cancer"},{"key":"1172_CR15","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ejca.2021.08.033","volume":"157","author":"WA Clarke","year":"2021","unstructured":"Clarke WA, Chatelut E, Fotoohi AK, Larson RA, Martin JH, Mathijssen RHJ, et al. Therapeutic drug monitoring in oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology consensus guidelines for imatinib therapy. Eur J Cancer. 2021;157:428\u201340.","journal-title":"Eur J Cancer"},{"key":"1172_CR16","unstructured":"US Food and Drug Administration. N21-588S020 imatinib clinical and statistical. 2006. https:\/\/www.fda.gov\/files\/N21-588S020-Imatinib-Clinical-and-Statistical.pdf. Accessed 27 Aug 2025."},{"key":"1172_CR17","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s40291-017-0292-x","volume":"21","author":"A Nath","year":"2017","unstructured":"Nath A, Wang J, Stephanie HR. Pharmacogenetics and pharmacogenomics of targeted therapeutics in chronic myeloid leukemia. Mol Diagn Ther. 2017;21:621\u201331.","journal-title":"Mol Diagn Ther"},{"key":"1172_CR18","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1007\/s11010-022-04376-6","volume":"477","author":"V Kumar","year":"2022","unstructured":"Kumar V, Singh P, Gupta SK, Ali V, Verma M. Transport and metabolism of tyrosine kinase inhibitors associated with chronic myeloid leukemia therapy: a review. Mol Cell Biochem. 2022;477:1261\u201379.","journal-title":"Mol Cell Biochem"},{"key":"1172_CR19","doi-asserted-by":"crossref","first-page":"7394","DOI":"10.1158\/1078-0432.CCR-07-0346","volume":"13","author":"NP van Erp","year":"2007","unstructured":"van Erp NP, Gelderblom H, Karlsson MO, Li J, Zhao M, Ouwerkerk J, et al. Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinib. Clin Cancer Res. 2007;13:7394\u2013400.","journal-title":"Clin Cancer Res"},{"key":"1172_CR20","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/bcp.12267","volume":"79","author":"HK Batchelor","year":"2015","unstructured":"Batchelor HK, Marriott JF. Paediatric pharmacokinetics: key considerations. Br J Clin Pharmacol. 2015;79:395\u2013404.","journal-title":"Br J Clin Pharmacol"},{"key":"1172_CR21","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1080\/17512433.2018.1398644","volume":"11","author":"M Suttorp","year":"2018","unstructured":"Suttorp M, Bornh\u00e4user M, Metzler M, Millot F, Schleyer E. Pharmacology and pharmacokinetics of imatinib in pediatric patients. Expert Rev Clin Pharmacol. 2018;11:219\u201331.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"1172_CR22","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3389\/fphar.2020.00177","volume":"11","author":"T Buclin","year":"2020","unstructured":"Buclin T, Thoma Y, Widmer N, Andr\u00e9 P, Guidi M, Csajka C, et al. The steps to therapeutic drug monitoring: a structured approach illustrated with imatinib. Front Pharmacol. 2020;11:177.","journal-title":"Front Pharmacol"},{"key":"1172_CR23","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/psp4.12195","volume":"6","author":"E Schindler","year":"2017","unstructured":"Schindler E, Krishnan SM, Mathijssen R, Ruggiero A, Schiavon G, Friberg LE. Pharmacometric modeling of liver metastases\u2019 diameter, volume, and density and their relation to clinical outcome in imatinib-treated patients with gastrointestinal stromal tumors. CPT Pharmacometr Syst Pharmacol. 2017;6:449\u201357.","journal-title":"CPT Pharmacometr Syst Pharmacol"},{"key":"1172_CR24","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2165\/11596990-000000000-00000","volume":"51","author":"V Gotta","year":"2012","unstructured":"Gotta V, Widmer N, Montemurro M, Leyvraz S, Haouala A, Decosterd LA, et al. Therapeutic drug monitoring of imatinib: Bayesian and alternative methods to predict trough levels. Clin Pharmacokinet. 2012;51:187\u2013201.","journal-title":"Clin Pharmacokinet"},{"key":"1172_CR25","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.cca.2011.02.023","volume":"412","author":"S Bouchet","year":"2011","unstructured":"Bouchet S, Chauzit E, Ducint D, Castaing N, Canal-Raffin M, Moore N, et al. Simultaneous determination of nine tyrosine kinase inhibitors by 96-well solid-phase extraction and ultra performance LC\/MS\u2013MS. Clin Chim Acta. 2011;412:1060\u20137.","journal-title":"Clin Chim Acta"},{"key":"1172_CR26","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1111\/bcp.12830","volume":"81","author":"C-Y Zhao","year":"2016","unstructured":"Zhao C-Y, Jiao Z, Mao J-J, Qiu X-Y. External evaluation of published population pharmacokinetic models of tacrolimus in adult renal transplant recipients. Br J Clin Pharmacol. 2016;81:891\u2013907.","journal-title":"Br J Clin Pharmacol"},{"key":"1172_CR27","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/bcp.13431","volume":"84","author":"J-J Mao","year":"2018","unstructured":"Mao J-J, Jiao Z, Yun H-Y, Zhao C-Y, Chen H-C, Qiu X-Y, et al. External evaluation of population pharmacokinetic models for ciclosporin in adult renal transplant recipients. Br J Clin Pharmacol. 2018;84:153\u201371.","journal-title":"Br J Clin Pharmacol"},{"key":"1172_CR28","doi-asserted-by":"crossref","first-page":"665","DOI":"10.3390\/pharmaceutics15020665","volume":"15","author":"C Leven","year":"2023","unstructured":"Leven C, M\u00e9nard P, Gouin-Thibault I, Ballerie A, Lacut K, Ollier E, et al. Transferability of published population pharmacokinetic models for apixaban and rivaroxaban to subjects with obesity treated for venous thromboembolism: a systematic review and external evaluations. Pharmaceutics. 2023;15:665.","journal-title":"Pharmaceutics"},{"key":"1172_CR29","volume":"203","author":"R Li","year":"2024","unstructured":"Li R, Sun F, Feng Z, Zhang Y, Lan Y, Yu H, et al. Evaluation and application of population pharmacokinetic models for optimising linezolid treatment in non-adherence multidrug-resistant tuberculosis patients. Eur J Pharm Sci. 2024;203: 106915.","journal-title":"Eur J Pharm Sci"},{"key":"1172_CR30","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00280-022-04454-y","volume":"90","author":"Y-H Chien","year":"2022","unstructured":"Chien Y-H, W\u00fcrthwein G, Zubiaur P, Posocco B, Pena M\u00c1, Borobia AM, et al. Population pharmacokinetic modelling of imatinib in healthy subjects receiving a single dose of 400 mg. Cancer Chemother Pharmacol. 2022;90:125\u201336.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1172_CR31","doi-asserted-by":"crossref","first-page":"96","DOI":"10.12793\/tcp.2016.24.2.96","volume":"24","author":"G Park","year":"2016","unstructured":"Park G, Park W-S, Bae S, Park S, Han S, Yim D-S. Population pharmacokinetics of imatinib mesylate in healthy Korean subjects. Transl Clin Pharmacol. 2016;24:96.","journal-title":"Transl Clin Pharmacol"},{"key":"1172_CR32","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s13318-015-0292-3","volume":"41","author":"A-A Golabchifar","year":"2016","unstructured":"Golabchifar A-A, Rezaee S, Dinan NM, Kebriaeezadeh A, Rouini M-R. Population pharmacokinetic analysis of the oral absorption process and explaining intra-subject variability in plasma exposures of imatinib in healthy volunteers. Eur J Drug Metab Pharmacokinet. 2016;41:527\u201339.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"1172_CR33","doi-asserted-by":"crossref","first-page":"6073","DOI":"10.1158\/1078-0432.CCR-05-2596","volume":"12","author":"C Delbaldo","year":"2006","unstructured":"Delbaldo C, Chatelut E, R\u00e9 M, Deroussent A, S\u00e9ronie-Vivien S, Jambu A, et al. Pharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors. Clin Cancer Res. 2006;12:6073\u20138.","journal-title":"Clin Cancer Res"},{"key":"1172_CR34","doi-asserted-by":"crossref","first-page":"7102","DOI":"10.1158\/1078-0432.CCR-08-0950","volume":"14","author":"A Petain","year":"2008","unstructured":"Petain A, Kattygnarath D, Azard J, Chatelut E, Delbaldo C, Geoerger B, et al. Population pharmacokinetics and pharmacogenetics of imatinib in children and adults. Clin Cancer Res. 2008;14:7102\u20139.","journal-title":"Clin Cancer Res"},{"key":"1172_CR35","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1111\/j.1365-2125.2012.04422.x","volume":"75","author":"A Haouala","year":"2013","unstructured":"Haouala A, Widmer N, Guidi M, Montemurro M, Leyvraz S, Buclin T, et al. Prediction of free imatinib concentrations based on total plasma concentrations in patients with gastrointestinal stromal tumours. Br J Clin Pharmacol. 2013;75:1007\u201318.","journal-title":"Br J Clin Pharmacol"},{"key":"1172_CR36","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/bcp.12584","volume":"80","author":"D Renard","year":"2015","unstructured":"Renard D, Bouillon T, Zhou P, Flesch G, Quinn D. Pharmacokinetic interactions among imatinib, bosentan and sildenafil, and their clinical implications in severe pulmonary arterial hypertension. Br J Clin Pharmacol. 2015;80:75\u201385.","journal-title":"Br J Clin Pharmacol"},{"key":"1172_CR37","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1002\/jcph.953","volume":"57","author":"BA Adeagbo","year":"2017","unstructured":"Adeagbo BA, Olugbade TA, Durosinmi MA, Bolarinwa RA, Ogungbenro K, Bolaji OO. Population pharmacokinetics of imatinib in Nigerians with chronic myeloid leukemia: clinical implications for dosing and resistance. J Clin Pharmacol. 2017;57:1554\u201363.","journal-title":"J Clin Pharmacol"},{"key":"1172_CR38","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1365-2125.2005.02372.x","volume":"60","author":"H Schmidli","year":"2005","unstructured":"Schmidli H, Peng B, Riviere G-J, Capdeville R, Hensley M, Gathmann I, et al. Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: results of a phase III study. Br J Clin Pharmacol. 2005;60:35\u201344.","journal-title":"Br J Clin Pharmacol"},{"key":"1172_CR39","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1365-2125.2006.02719.x","volume":"62","author":"N Widmer","year":"2006","unstructured":"Widmer N, Decosterd LA, Csajka C, Leyvraz S, Duchosal MA, Rosselet A, et al. Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein. Br J Clin Pharmacol. 2006;62:97\u2013112.","journal-title":"Br J Clin Pharmacol"},{"key":"1172_CR40","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s00280-008-0730-x","volume":"63","author":"D Menon-Andersen","year":"2009","unstructured":"Menon-Andersen D, Mondick JT, Jayaraman B, Thompson PA, Blaney SM, Bernstein M, et al. Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults. Cancer Chemother Pharmacol. 2009;63:229\u201338.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1172_CR41","doi-asserted-by":"crossref","first-page":"5780","DOI":"10.1158\/1078-0432.CCR-12-0490","volume":"18","author":"K Eechoute","year":"2012","unstructured":"Eechoute K, Fransson MN, Reyners AK, de Jong FA, Sparreboom A, van der Graaf WTA, et al. A long-term prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patients. Clin Cancer Res. 2012;18:5780\u20137.","journal-title":"Clin Cancer Res"},{"key":"1172_CR42","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/tpj.2014.7","volume":"14","author":"A Di Paolo","year":"2014","unstructured":"Di Paolo A, Polillo M, Capecchi M, Cervetti G, Barat\u00e8 C, Angelini S, et al. The c.480C>G polymorphism of hOCT1 influences imatinib clearance in patients affected by chronic myeloid leukemia. Pharmacogenom J. 2014;14:328\u201335.","journal-title":"Pharmacogenom J."},{"key":"1172_CR43","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.leukres.2014.03.023","volume":"38","author":"V Gotta","year":"2014","unstructured":"Gotta V, Bouchet S, Widmer N, Schuld P, Decosterd LA, Buclin T, et al. Large-scale imatinib dose-concentration-effect study in CML patients under routine care conditions. Leuk Res. 2014;38:764\u201372.","journal-title":"Leuk Res"},{"key":"1172_CR44","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s00280-004-0876-0","volume":"55","author":"I Judson","year":"2005","unstructured":"Judson I, Ma P, Peng B, Verweij J, Racine A, di Paola ED, et al. Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group. Cancer Chemother Pharmacol. 2005;55:379\u201386.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1172_CR45","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2217\/pgs-2018-0139","volume":"20","author":"Q Wang","year":"2019","unstructured":"Wang Q, Jiang Z-P, Yu E-Q, Zeng J, Zhu Y, Cai H-L, et al. Population pharmacokinetic and pharmacogenetics of imatinib in Chinese patients with chronic myeloid leukemia. Pharmacogenomics. 2019;20:251\u201360.","journal-title":"Pharmacogenomics"},{"key":"1172_CR46","first-page":"244","volume":"33","author":"Y Yamakawa","year":"2011","unstructured":"Yamakawa Y, Hamada A, Nakashima R, Yuki M, Hirayama C, Kawaguchi T, et al. Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011;33:244\u201350.","journal-title":"Ther Drug Monit"},{"key":"1172_CR47","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00280-023-04581-0","volume":"92","author":"S He","year":"2023","unstructured":"He S, Shao Q, Zhao J, Bian J, Zhao Y, Hao X, et al. Population pharmacokinetics and pharmacogenetics analyses of imatinib in Chinese patients with chronic myeloid leukemia in a real-world situation. Cancer Chemother Pharmacol. 2023;92:399\u2013410.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1172_CR48","doi-asserted-by":"crossref","first-page":"809","DOI":"10.2147\/DDDT.S400986","volume":"17","author":"X Jiang","year":"2023","unstructured":"Jiang X, Fu Q, Jing Y, Kong Y, Liu H, Peng H, et al. Personalized dose of adjuvant imatinib in patients with gastrointestinal stromal tumors: results from a population pharmacokinetic analysis. Drug Des Dev Ther. 2023;17:809\u201320.","journal-title":"Drug Des Dev Ther"},{"key":"1172_CR49","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1007\/s00228-022-03345-8","volume":"78","author":"B Shriyan","year":"2022","unstructured":"Shriyan B, Mehta P, Patil A, Jadhav S, Kumar S, Puri AS, et al. Role of ADME gene polymorphisms on imatinib disposition: results from a population pharmacokinetic study in chronic myeloid leukaemia. Eur J Clin Pharmacol. 2022;78:1321\u201330.","journal-title":"Eur J Clin Pharmacol"},{"key":"1172_CR50","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s00280-014-2473-1","volume":"74","author":"A-A Golabchifar","year":"2014","unstructured":"Golabchifar A-A, Rezaee S, Ghavamzadeh A, Alimoghaddam K, Dinan NM, Rouini M-R. Population pharmacokinetics of imatinib in Iranian patients with chronic-phase chronic myeloid leukemia. Cancer Chemother Pharmacol. 2014;74:85\u201393.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1172_CR51","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1007\/s11095-022-03273-3","volume":"39","author":"L Yang","year":"2022","unstructured":"Yang L, Yang N, Yi B, Pei Q, Huang Z. Population pharmacokinetic evaluation with external validation of tacrolimus in Chinese primary nephrotic syndrome patients. Pharm Res. 2022;39:1907\u201320.","journal-title":"Pharm Res"},{"key":"1172_CR52","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3390\/antibiotics12020301","volume":"12","author":"M Mena","year":"2023","unstructured":"Mena M, Garcia J-C, Bustos R-H. Implementing vancomycin population pharmacokinetic models: an App for individualized antibiotic therapy in critically ill patients. Antibiotics (Basel). 2023;12:301.","journal-title":"Antibiotics (Basel)"},{"key":"1172_CR53","volume":"13","author":"J Mao","year":"2022","unstructured":"Mao J, Li Q, Li P, Qin W, Chen B, Zhong M. Evaluation and application of population pharmacokinetic models for identifying delayed methotrexate elimination in patients with primary central nervous system lymphoma. Front Pharmacol. 2022;13: 817673.","journal-title":"Front Pharmacol"},{"key":"1172_CR54","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1111\/bcp.15122","volume":"88","author":"\u00c1 Corral Alaejos","year":"2022","unstructured":"Corral Alaejos \u00c1, Zarzuelo Casta\u00f1eda A, Jim\u00e9nez Cabrera S, S\u00e1nchez-Guijo F, Otero MJ, P\u00e9rez-Blanco JS. External evaluation of population pharmacokinetic models of imatinib in adults diagnosed with chronic myeloid leukaemia. Br J Clin Pharmacol. 2022;88:1913\u201324.","journal-title":"Br J Clin Pharmacol"},{"key":"1172_CR55","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00280-024-04644-w","volume":"94","author":"JS Dilli Batcha","year":"2024","unstructured":"Dilli Batcha JS, Gota V, Matcha S, Raju AP, Rao M, Udupa KS, et al. Predictive performance of population pharmacokinetic models of imatinib in chronic myeloid leukemia patients. Cancer Chemother Pharmacol. 2024;94:35\u201344.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1172_CR56","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/cpt.1808","volume":"108","author":"JM Janssen","year":"2020","unstructured":"Janssen JM, Dorlo TPC, Steeghs N, Beijnen JH, Hanff LM, van Eijkelenburg NKA, et al. Pharmacokinetic targets for therapeutic drug monitoring of small molecule kinase inhibitors in pediatric oncology. Clin Pharmacol Ther. 2020;108:494\u2013505.","journal-title":"Clin Pharmacol Ther"},{"key":"1172_CR57","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1111\/bcp.13901","volume":"85","author":"JA Abrantes","year":"2019","unstructured":"Abrantes JA, J\u00f6nsson S, Karlsson MO, Nielsen EI. Handling interoccasion variability in model-based dose individualization using therapeutic drug monitoring data. Br J Clin Pharmacol. 2019;85:1326\u201336.","journal-title":"Br J Clin Pharmacol"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-025-01172-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-025-01172-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-025-01172-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T13:10:45Z","timestamp":1758719445000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-025-01172-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":57,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["1172"],"URL":"https:\/\/doi.org\/10.1007\/s11523-025-01172-2","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"23 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research is funded by the University of Copenhagen and the Copenhagen University Hospital. The work was supported by Danish Childhood Cancer Foundation (project number 2021-7410 and 2022-8178), Arvid Nilssons Foundation, Director Michael Hermann Nielsen\u2019s Memorial Foundation (project number 2022-0097724), Engineer Otto Christensen's Foundation, and Manufacturer Einar Willumsen\u2019s Memorial Foundation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Tianwu Yang, Anna Sofie Buhl Rasmussen, Allan Weimann, Maria Thastrup, Cecilie Utke Rank, Bodil Als-Nielsen, Johan Malmros, Hilde Skuterud Wik, Olli Lohi, Overgaard, Inga Maria Rinvoll Johannsdottir, Goda Vaitkeviciene, Kim Dalhoff, Kjeld Schmiegelow, and Trine Meldgaard Lund have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/competing interests"}},{"value":"This study has received approval from the local ethics committee. All procedures involving human subjects were performed following the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All participants provided written informed consent.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The data of this study are available from the corresponding author upon reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"TY: conceptualization; data curation; formal analysis; investigation; methodology; software; validation; visualization; writing (original draft); writing (review and editing). ASBR: conceptualization; data curation; investigation; resources; writing (review and editing). AW and MT: data curation; resources; writing (review and editing). CUR, BA-N, JM, HSW, OL, UO, IMRJ, and KD: resources; writing (review and editing). KS: funding acquisition; project administration; resources; supervision; writing (review and editing). TML: conceptualization; funding acquisition; project administration; resources; supervision; writing (review and editing).","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}